Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03189706 · ClinicalTrials.gov registry record · Early Phase 1
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
A Early Phase 1 study of Neuroblastoma (NB), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT03189706 is a Early Phase 1 study of Neuroblastoma (NB) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 48 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03189706, a Early Phase 1 study of Neuroblastoma (NB), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether an experimental drug called Hu3F8 can be given with the chemotherapy drugs irinotecan and temozolomide and another drug called GM-CSF. The investigators want to find out if this combination is safe and what effect it has on the participant and the disease.
Conditions Studied
Interventions
- DRUG Irinotecan
- DRUG GM-CSF
- DRUG temozolomide
- BIOLOGICAL Hu3F8
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-06-12 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03189706
The ClinicalTrials.gov registry entry for NCT03189706 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma (NB) appearing as the primary indexed condition, and to 4 interventions - of which Irinotecan is the first listed.
NCT03189706 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03189706 about?
NCT03189706 is a clinical study titled "Study of Chemoimmunotherapy for High-Risk Neuroblastoma". The purpose of this study is to find out whether an experimental drug called Hu3F8 can be given with the chemotherapy drugs irinotecan and temozolomide and another drug called GM-CSF. The investigators want to find out if this combination is safe and what effect it has on the participant and the dis...
What is the current status of trial NCT03189706?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2017-06-12. Estimated completion is 2026-06.
What conditions does trial NCT03189706 study?
This clinical trial studies the following conditions: Neuroblastoma (NB).
What interventions are being tested in trial NCT03189706?
The interventions under investigation include: Irinotecan (DRUG), GM-CSF (DRUG), temozolomide (DRUG), Hu3F8 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03189706?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03189706 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.